Martilias S Farrell

8PUBLICATIONS
41CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Neurology and neuromuscular diseasesGene expression (incl. microarray and other genome-wide approaches)NeurogeneticsBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 06, 2026
3D-genome impacts of TAD-boundary-disrupting ultra-rare structural variants identified in schizophrenia.

|Jun 04, 2025
Medical Multimorbidity in Patients with Treatment-Resistant Psychosis and Rare Copy Number Variants: A Retrospective Case Series of 24 Patients.

Tyler E Dietterich, Rose Mary Xavier, Maya L Lichtenstein

|Nov 15, 2022
Rare tandem repeat expansions associate with genes involved in synaptic and neuronal signaling functions in schizophrenia.

Jia Wen, Brett Trost, Worrawat Engchuan

|Apr 17, 2020
Increased burden of ultra-rare structural variants localizing to boundaries of topologically associated domains in schizophrenia.

Matthew Halvorsen, Ruth Huh, Nikolay Oskolkov

|Feb 19, 2020
Treatment-resistant psychotic symptoms and the 15q11.2 BP1-BP2 (Burnside-Butler) deletion syndrome: case report and review of the literature.

Martilias Farrell, Maya Lichtenstein, Matthew K Harner

|Mar 03, 2018
The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.

Daniel F Manvich, Kevin A Webster, Stephanie L Foster

Pageof 2

Frequent Collaborators

4 joint publications

Jin P Szatkiewicz

3 joint publications

Paola Giusti-Rodriguez

3 joint publications

Patrik K E Magnusson

2 joint publications

Nikolay Oskolkov